Bristol-Myers Squibb Company Release: AVERT Trial Demonstrates High Rates Of DAS-Defined Remission With Orencia® (Abatacept) In Combination With Methotrexate (MTX) In Adult Patients With Early Rheumatoid Arthritis (RA)
Published: Jun 11, 2014
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today its first release of new data from a Phase IIIb RA trial showing that the T-cell co-stimulation modulator, Orencia ® (abatacept), in combination with methotrexate (MTX) achieved significantly higher rates of DAS-defined (DAS28 CRP <2.6) remission at 12 months than treatment with standard of care agent MTX (60.9% vs. 45.2%, respectively), in biologic and MTX-naïve patients with early active RA. The data are being presented this week at the 2014 annual meeting of the European League Against Rheumatism (EULAR).
Help employers find you! Check out all the jobs and post your resume.